Clinical Trial Update: A Clinical Study of Iparomlimab and Tuvonralimab Combined With Fruquintinib and Heterogeneous Radiotherapy Versus Fruquintinib as Third-Line and Subsequent-Line Treatment for Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial protocol evaluating iparomlimab and tuvonralimab in combination with fruquintinib and heterogeneous radiotherapy versus fruquin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Fruquintinib (fruquintinib)
• Tuvonralimab (tuvonralimab)
• iparomlimab

Snippet

Sponsor: Huazhong University of Science and Technology | Conditions: Metastatic Colorectal Cancer (CRC), mCRC | Phase 2 | Status: NOT_YET_RECRUITING